42 studies found for:    " January 16, 2008":" February 15, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Active, not recruiting A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial
Condition: HIV Infections
Intervention: Genetic: VRX496-transduced autologous CD4 T cells
22 Completed Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4
Conditions: HIV Infections;   Hepatitis C
Intervention: Drug: Peginterferon alfa-2a + ribavirin
23 Completed ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla
Condition: HIV Infections
Intervention: Drug: Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg
24 Completed Cognitive Stimulation Program in AIDS
Condition: HIV Infections
Intervention: Behavioral: Smartbrain
25 Completed Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese Patients:Multicentric Observation Cohort
Condition: HIV Infections
Interventions: Drug: Zidovudine (AZT)+ Didanosine (ddI)+ Nevirapine (NVP);   Drug: Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP);   Drug: Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP)
26 Completed Italian Prospective Data Collection for Better Patient Characterization in a Highly Treatment Experienced Population
Condition: HIV Infections
Intervention: Drug: TPV
27 Completed Pharmacokinetics of Low Dose Ritonavir
Condition: HIV Infections
Intervention: Drug: ritonavir and saquinavir
28 Completed INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Condition: HIV Infections
Interventions: Drug: enfuvirtide [Fuzeon];   Drug: Optimized background ARV therapy
29 Unknown  Efficacy of Group Intervention to Reduce Stress Symptoms
Conditions: Stress Disorders, Post-Traumatic;   HIV Infections
Intervention: Behavioral: HIV Skills-based Prevention
30 Completed Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification Strategy
Condition: HIV Infections
Interventions: Drug: Darunavir 900mg + ritonavir 100 mg once a day;   Drug: Darunavir 600mg + ritonavir 100mg twice day
31 Withdrawn Safety and Tolerability of a Therapeutic DNA Dendritic Cell Vaccine in HIV-Infected Children, Adolescents, and Young Adults
Condition: HIV Infections
Interventions: Biological: DermaVir patch;   Biological: Placebo patch
32 Completed Pharmacokinetic Study on Raltegravir and Lamotrigine
Condition: HIV Infection
Interventions: Drug: lamotrigine;   Drug: Raltegravir
33 Withdrawn Bioequivalence Study of Generic GPO Saquinavir and Norvir® Versus Invirase® and Norvir®
Condition: HIV Infections
Intervention: Drug: generic GPO saquinavir and novir vs invirase and norvir
34 Completed Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis
Conditions: HIV Infections;   Tuberculosis
Interventions: Drug: Nevirapine without dose escalation;   Drug: Nevirapine initiation with dose escalation
35 Completed Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 Hours
Condition: HIV Infections
Intervention: Drug: tipranavir/ritonavir (dose reduction)
36 Completed Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)
Condition: HIV Infections
Intervention: Behavioral: NO BI Drug administered
37 Completed Pharmacokinetics of Generic Lopinavir/Ritonavir in Pregnant Women
Condition: HIV Infections
Intervention: Drug: generic lopinavir/ritonavir
38 Completed
Has Results
Pharmaco-epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safety & Efficacy
Condition: HIV Infections
Intervention: Drug: tipranavir
39 Active, not recruiting An Educational and Supportive Counseling Program for Increasing Antiretroviral Use and Adherence in People With HIV
Condition: HIV
Interventions: Behavioral: Counseling sessions;   Behavioral: Group workshop
40 Unknown  Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV
Conditions: Chronic Hepatitis C;   Co-Infection HIV-HCV
Intervention: Drug: Peg interferon + Ribavirin

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-42) Show next page of results
Indicates status has not been verified in more than two years